BJU International

OBJECTIVES: Non-muscle-invasive bladder cancer that is refractory to intravesical Bacillus Calmette-Guérin (BCG) may be treated by systemic anti-PD-1 (programmed cell death protein 1) immunotherapy. We previously demonstrated improved overall survival with 6 weekly instillations of intravesical anti-PD-1 in a murine model. The objective of this work is to test if intravesical instillation of both an anti-PD-1 inhibitor and an oncolytic reovirus would demonstrate a greater effect than either treatment alone...

OBJECTIVES: To assess long-term voiding and renal function (RF) changes after radical cystectomy (RC) and orthotopic neobladder (ONB) in females without disease recurrence. MATERIAL AND METHODS: Female patients who underwent RC and ONB from 1995 and 2011 were included. Patients who developed disease failure or lost follow-up were excluded. The study outcomes were long-term voiding function and the incidence and predictors of RF deterioration (defined by > 20% decline of baseline)...

No abstract text is available yet for this article.

OBJECTIVES: Controversial findings have been shown about the effect of warm ischemia time (WIT) on renal function in patients undergoing partial nephrectomy (PN). Specifically, it is unclear whether the surgical risk of performing off-clamp PN overcomes its beneficial effect on kidney function after surgery. In consequence, we tested the hypothesis that longer WIT might have a marginal impact on renal functional outcomes and, on the contrary, might reduce the hemorrhagic risk intraoperatively...

No abstract text is available yet for this article.

No abstract text is available yet for this article.

OBJECTIVES: To evaluate the reliability of trans-perineal laser ablation of prostate (TPLA) in preserving antegrade ejaculation compared to trans-urethral resection of prostate (TURP). PATIENTS AND METHODS: In this single-center, prospective, randomized, open-label study, consecutive patients with indication to surgical treatment for benign prostatic obstruction (BPO) were enrolled between January 2020 and September 2021 (NCT04781049). Randomization defined two treatment arms: Group A: patients assigned to TPLA (experimental); Group B: patients assigned to TURP (standard)...

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

OBJECTIVES: To report a single centre's experience of the feasibility, safety and patient acceptability of same day discharge Robot-Assisted Laparoscopic Prostatectomy (RALP). SUBJECTS/PATIENTS AND METHODS: Between June 2015 and December 2021, a total of 180 pre-selected consecutive patients underwent RALP with the intention to discharge on the same day as surgery. Cases were performed by two surgeons. An Enhanced Recovery After Surgery (ERAS) programme was utilised...

OBJECTIVES: The use of mpMRI has been a significant advance in the diagnosis of clinically significant prostate cancer (ISUP Grade Group ≥2, csPCa) and is recommended in most current guidelines. Proclarix® is a novel CE-marked biomarker test aiding in the identification of csPCa. The aim of the study was the assessment of the clinical performance of Proclarix alone or in combination with mpMRI to predict csPCa. PATIENTS AND METHODS: The study included blood samples from 721 men undergoing mpMRI followed by biopsy at University College London (UCL), London, and Vall d'Hebron University Hospital, Barcelona...

OBJECTIVES: To compare the incidence of subsequent prostate cancer diagnosis and death following an initial non-malignant systematic TRUS biopsy to an age- and calendar-year matched population over a 20-year period. SUBJECTS AND METHODS: This population-based analysis compares a cohort of all men with initial non-malignant TRUS biopsy in Denmark between 1995-2016 (N=37,231) to the Danish population matched by age and calendar year, obtained from the NORDCAN 9.1 database...

No abstract text is available yet for this article.

OBJECTIVE: To provide the first clinical validation of the EAU Robotic Urology Section (ERUS) curriculum for Robotic-Assisted Radical Cystectomy with intracorporeal urinary diversion (iRARC) training. The ERUS proposed a structured curriculum, divided in 11steps, to train novice surgeons and help overcome the steep learning curve of iRARC. No pilot clinical validation is available to date. PATIENTS AND METHODS: One trainee completed the curriculum under the mentorship of an expert...

OBJECTIVES: To describe outcomes of oral mucosal graft ureteroplasty (OMGU) and ileal ureter replacement (IUR) and determine the relative merits of both procedures. METHODS: Databases (including PubMed, Embase and Cochrane) were interrogated for eligible trials that assessed outcomes of OMGU or IUR from 2000 to 30 July 2022. The variables analysed were reconstruction success rates, stricture length, hospital stays, perioperative complications and long-term complications...

OBJECTIVE: To profile cell-free urine supernatant and plasma of a small cohort of ccRCC patients by measuring the relative concentrations of 92 proteins related to inflammation. Using The Cancer Genome Atlas (TCGA), we then performed a targeted mRNA analysis of genes encoding the above proteins and defined their effects on overall survival (OS). SUBJECTS/PATIENTS AND METHODS: Samples were collected prospectively from ccRCC patients. A multiplex proximity extension assay was used to measure the concentrations of 92 inflammation-related proteins in cell-free urine supernatants and plasma...

OBJECTIVE: To assess the efficacy of 177 Lu-PNT2002, a novel radiolabelled small molecule that binds with high affinity to prostate-specific membrane antigen (PSMA), in combination with stereotactic body radiotherapy (SBRT) to all sites of metastasis, vs SBRT alone, in men with oligorecurrent metastatic hormone-sensitive prostate cancer (mHSPC). PATIENTS AND METHODS: The 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR) trial is an open-label, randomized, stratified, two-arm, single-centre, Phase 2 trial to compare the efficacy and safety of neoadjuvant 177 Lu-PNT2002 plus SBRT vs SBRT alone in men with oligorecurrent mHSPC...